The ongoing phase I/II CodeBreaK 100 clinical trial (ClinicalTrials.gov ID NCT03600883) is designed to investigate the safety, tolerability, and efficacy of sotorasib in patients with various solid tumors, including pancreatic cancer, harboring KRAS G12C mutations. This evidence concerns the gene KRAS and familial pancreatic carcinoma.